Valsartan tablets
Reason category: Dissolution failure
FDA recall number D-0746-2026
Blood pressure
Valsartan 160 mg tablet
Public data on valsartan from CMS and FDA: what pharmacies have paid for it, how many generic applications FDA has approved, and whether it appears in FDA's shortage or recall records.
$0.1057
NADAC per ea (2026-11)
approximate acquisition cost, not a retail price
-61%
change over five years
peak $3.3552 in 2014-09
24
approved generic applications (ANDAs) on record for Valsartan
18 with a product still marketed · first 2014
Not listed
in FDA's current shortage list
Valsartan Tablet: To Be Discontinued
NADAC per unit, monthly
VALSARTAN 160 MG TABLETShow as table
| Month | NADAC per unit ($) |
|---|---|
| 2014-09 | 3.35515 |
| 2014-12 | 3.20948 |
| 2015-03 | 2.15690 |
| 2015-06 | 0.43282 |
| 2015-09 | 0.38411 |
| 2015-12 | 0.36418 |
| 2016-03 | 0.35698 |
| 2016-06 | 0.34851 |
| 2016-09 | 0.30876 |
| 2016-12 | 0.20902 |
| 2017-03 | 0.16867 |
| 2017-06 | 0.12915 |
| 2017-09 | 0.12956 |
| 2017-12 | 0.11172 |
| 2018-03 | 0.10609 |
| 2018-06 | 0.09743 |
| 2018-09 | 0.11814 |
| 2018-12 | 0.36963 |
| 2019-03 | 0.28363 |
| 2019-06 | 0.31673 |
| 2019-09 | 0.29131 |
| 2019-12 | 0.29970 |
| 2020-03 | 0.32314 |
| 2020-06 | 0.35157 |
| 2020-09 | 0.35744 |
| 2020-12 | 0.28894 |
| 2021-03 | 0.28450 |
| 2021-06 | 0.29492 |
| 2021-09 | 0.28135 |
| 2021-12 | 0.27415 |
| 2022-03 | 0.24500 |
| 2022-06 | 0.23356 |
| 2022-09 | 0.22926 |
| 2022-12 | 0.23492 |
| 2023-03 | 0.21966 |
| 2023-06 | 0.19987 |
| 2023-09 | 0.18852 |
| 2023-12 | 0.19643 |
| 2024-03 | 0.19251 |
| 2024-06 | 0.16812 |
| 2024-09 | 0.18506 |
| 2024-12 | 0.14267 |
| 2025-03 | 0.16236 |
| 2025-06 | 0.16531 |
| 2025-09 | 0.15197 |
| 2025-12 | 0.13926 |
| 2026-03 | 0.13978 |
| 2026-06 | 0.13254 |
| 2026-09 | 0.11232 |
Source: CMS NADAC weekly files, generic rows, monthly median of weekly averages · data as of 2026-11. Figures can change and may contain errors in the source data. Check the original source before relying on them.
Recall records mentioning valsartan
openFDA enforcement records, by year reported.
| 2026 | 1 |
| 2021 | 1 |
| 2019 | 20 |
| 2018 | 103 |
| 2014 | 4 |
| 2013 | 9 |
138 records since 2012. A record is one product or lot, not one recall event. Combination products that contain valsartan are included.
What these numbers mean
NADAC is what retail pharmacies pay on average to buy the drug, published by CMS. It does not include rebates and is not what you pay at the counter. ANDA counts include all strengths and forms and applications whose products are now discontinued.
Most recent recall records
Valsartan tablets
Reason category: cGMP deviations
FDA recall number D-0461-2021
Valsartan product
Reason category: Impurities (e.g. nitrosamines)
FDA recall number D-1052-2019
Valsartan tablets usp
Reason category: Impurities (e.g. nitrosamines)
FDA recall number D-1047-2019
Valsartan product
Reason category: Impurities (e.g. nitrosamines)
FDA recall number D-1055-2019
Not health advice. GxRadar is for general information only. Nothing here is medical, pharmacy, legal or financial advice. Do not start, stop or change any medicine based on this site. Talk to your pharmacist or prescriber about your own situation.
Articles that mention valsartan
19 GxRadar articles cite or discuss this drug.
Case histories · Data story · 5 min
The valsartan recall and what it did to prices
After FDA's July 2018 valsartan recalls, the national average cost of a 160 mg tablet rose from 9.5 cents to 37 cents in five months. Eight years later it is still above its pre-recall level.
Price histories · Data story · 5 min
What pharmacies pay for seven blood pressure generics, 2014 and 2026
At federal survey rates, 365 tablets each of seven common blood pressure generics cost pharmacies about $95 in October 2026, down from $1,403 in October 2014. One drug explains most of the drop.
Case histories · History · 6 min
How a carcinogen in blood pressure pills changed generic drug testing
Since 2018, nitrosamine impurities have produced nearly 500 federal recall records, pushed ranitidine off the US market and led FDA to set daily intake limits for impurities formed from the drug itself.
Recall data · Data story · 6 min
The reasons drugs get recalled, counted from FDA's own records
A GxRadar count of 18,076 FDA drug recall records since 2012 shows a handful of failure types, led by sterility, manufacturing lapses, impurities and pills that dissolve out of spec.
Market economics · Explainer · 5 min
What happens to Medicaid spending when the first generic arrives
Federal research on prices after generic entry, and four worked examples from NADAC and Medicaid claims data: duloxetine, valsartan, rosuvastatin and tadalafil.
Distribution · Explainer · 6 min
Repackagers and relabelers, the firms that put generics in new bottles
How federal rules define repackagers and relabelers, why their NDCs and expiration dates differ from the original, and what FDA's NDC and recall data show about them.